With the launch of its new Innovation Unit on July 1, Boehringer Ingelheim GmbH is not only reorganizing its various research teams to streamline R&D, but is ramping up external partnerships to explore new biological concepts and technologies in anticipation of shifting market demands.
The company joins Sanofi and Novartis Institutes for BioMedical Research (NIBR), the research arm of Novartis AG, in announcing major restructuring of research this year, and all three are taking pains to emphasize that they are doubling down on external innovation.
For Boehringer, the impetus is the need to build in greater versatility to anticipate changes in medical needs and identify the technologies best suited to address them.
"The unmet medical needs of 10 years from now will be different, and may or may not align with our current therapeutic areas," said Clive Wood, senior corporate VP of discovery research at Boehringer.
While in the short term the therapeutic areas will remain cardiometabolic diseases, respiratory diseases, oncology, immunology and CNS disorders, Wood expects the company will